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Cardiac outputBackground: Attention-deficit hyperactivity disorder (ADHD) is one of the most prevalent psychiatric dis-
orders of childhood. It’s been suggested that both the condition and the medications used to treat it can
affect the cardiovascular system. This study aims to determine whether methylphenidate has the signif-
icant effects in cardiac indices.
Methods: In this prospective study, 100 newly ADHD-diagnosed children aged 6 to 11 whom all on
methylphenidate were included. The demographic, clinical data including the blood pressure and heart
rate (HR), echocardiographic, and QT-interval were recorded at baseline and after three months of
follow-up.
Results: After the follow-up period, we observed no abnormal systolic, diastolic, or mean arterial pressure
in any of the participants based on their age, height, and gender (p < 0.001). However, the mean of all
these variables was significantly increased (p h001). Mean pulse pressure was also higher than baseline
but it wasn’t statistically significant (p = 0.059). No significant change was observed in echocardiographic
parameters and QT.
Conclusion: Short-term treatment of ADHD in children with methylphenidate does not have a meaningful
relationship with hypertension and increased corrected QT interval. However, an increase in blood pres-
sure and corrected QT interval within a non-pathological range suggests that longer follow-ups may
reveal an association.
 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
ADHD is one of the most common neurodevelopmental disor-
ders, as defined in the DSM, 5th edition, described by symptoms
including inattention, hyperactivity, and impulsivity [1,2] The esti-
mated prevalence of ADHD in school-aged children ranges from 3%
to 10.2%, with the highest rates in North America and the United
States [3–5]. The rate is shown to be 3 times higher in boys than
in girls [6]. Studies indicate that between 3 types of ADHD, the
hyperactive-impulsive type and the inattentive type are prevalent
among boys and girls, respectively [7]. The potential of drugs used
to treat this disorder to adversely affect the cardiovascular systemhas cause concern about their safety, both in the normal popula-
tion and in those with a history of CVD who may be at higher risk
for cardiovascular complications with the use of these medications
[8–12]. ADHD symptoms are likely to occur due to impaired brain
dopaminergic pathways [13,14], and dopamine itself is shown to
be able to cause changes in the cardiovascular system [15,16].
Some previous studies have reported a significant reduction in
ADHD patients’ systolic and diastolic blood pressures compared
with controls and they have also suggested that more severe symp-
toms of the disease could result in greater blood pressure reduc-
tions [17]. On the other hand, some other studies suggest that
hypertension and ADHD are positively correlated, in addition, a
study on some children and adults revealed that while hyperten-
sion in adults is predominantly primary, it often appears to be
secondary –usually to medications- in children [18,19]. Interest-
ingly, some older studies have also shown associations between
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[20]. Evidence suggests that there is a large difference between the
effects of stimulant and non-stimulant drugs on blood pressure as
well as cardiac output. It seems that stimulants (including methyl-
phenidate and doxy-amphetamine medications) used to treat
ADHD can lead to a slight elevation in cardiac output as well as sys-
tolic and diastolic blood pressures [21–23]. Consequently, among
all available ADHD drugs, the CNS stimulants raise the highest con-
cern about cardiovascular complications. Stimulants increase the
release of noradrenergic and dopaminergic mediators and mimic
the effects of sympathetic stimulation, hence affecting the cardio-
vascular system [24–26]. Cardiovascular adverse effects of stimu-
lant drugs in children and adolescents are still controversial. The
risk for most patients is small but careful evaluation is needed
before and during stimulant prescription [16,27–30]. The purpose
of our study was to investigate the effects of short-term (three
months) medical therapy of children with ADHD in terms of blood
pressure, QT interval, and left ventricular velocity time integral
(LV-VTI).Table 1




Systole pressure 80.9 ± 11.37 85.2 ± 12.85 0.000*
Diastole pressure 45.45 ± 7.35 48.3 ± 9.46 0.000*
MAP 57.49 ± 8.26 60.83 ± 9.87 0.000*
pulse pressure 35.45 ± 8.58 36.9 ± 8.58 0.059
Heart rate 84 ± 9 88 ± 7 0.101
LVED d 3.84 ± 0.47 3.73 ± 0.47 0.052
LVES d 2.58 ± 0.45 2.56 ± 0.30 0.060
VTI 21.1 ± 3.1 21.2 ± 2.9 0.213
QTc 402 ± 36.0 406 ± 24.1 0.367
QT dispersion 57 ± 10.2 55 ± 8.6 0.353
Abbreviations: MAP: mean arterial pressure; VTI: velocity–time integral; QTc:
corrected QT; CO: cardiac output; LVEDd: Left Ventricle end-diastolic diameter;
LVESd: Left Ventricle end-systolic diameter; P-value < 0.05 is considered significant
and is shown with (*) in the table. P-value calculated with Paired Sample T-Test.2. Methods
2.1. Study description
This study was conducted in 2019 on 100 children aged 6 to
11 years who were referred to the psychiatric clinic of Ziaeian
Hospital in Tehran, Iran. The diagnosis of ADHD for all these chil-
dren was confirmed by a certified psychiatrist using DSM-V crite-
ria. All of the ADHD-diagnosed children were treated with
methylphenidate. After being rested for at least 5 min in the
stretched legs position, the blood pressure of each patient was
measured three times using the Microlife blood pressure monitor-
ing device. The mean of the second and third measured systolic
and diastolic blood pressure values stored as baseline information.
The pulse pressure was also calculated by subtracting diastolic
pressure from systolic pressure. Hypertension in children and ado-
lescents defined based on their age, gender, height, and percentile.
BP categories and stages were defined by the 2017 American Acad-
emy of Pediatrics High Blood Pressure Guideline [31]. The Seca
altimeter (made in Germany) was used to measure the height of
the subjects with a precision of one millimeter. To measure their
weights, we used the Seca digital scale (made in Germany) with
a precision of 0.1 kg. The body mass index (BMI) of the children
was calculated individually. Patients who underwent transthoracic
echocardiography and left ventricular end-diastolic and systolic
diameter, and LV-VTI were recorded. The stroke volume (SV) is
procured from the product of the left ventricular outflow tract
(LVOT) cross-sectional area (CSA, in cm2) with the LVOT-VTI
(known as stroke distance, in cm). The LVOT-CSA is derived from
the LVOT diameter (LVOTd) using the formula pr2 (3.1416 
(LVOTd/2)2), or its equivalent (LVOTd)2  0.785. The LVOTd is
obtained from the parasternal long-axis view, at a mid-systolic
frame, measured from the inner edge to the outer edge of the LVOT
or eventually between the site of insertion of the right- and non-
coronary aortic leaflets [32,33]. The LVOT VTI is acquired by tracing
the envelope of the Doppler spectrum of LVOT systolic flow from
the apical five- or three-chamber view using pulsed-wave Doppler
(PWD), with the sample volume placed within the LVOT, approxi-
mately at 1 cm distance to the aortic valve [32]. The product of the
SV and heart rate (HR) will yield the cardiac output (CO, in L/min)
[33]. QT interval is defined as the interval between Q wave and ter-
mination of T wave in surface electrocardiogram (ECG). Patients
were then asked to return to the clinic after three months for a
re-evaluation of all the previously measured variables. Those2
who had discontinued their medications or had changed them in
this period were excluded from the study.
2.2. Ethics statement
In terms of ethics, the purpose of the study was explained to the
families of all children and they were given the right not to partic-
ipate. Their will to participate in the study was solidified using
written consent. The study protocol was approved by the Ethics
Committee of Tehran University of Medical Sciences (ethical code:
95–03-30–32906).
2.3. Statistical analysis
Finally, all available data were entered into SPSS 24.0 (Statisti-
cal Package for Social Science Inc., Chicago, Illinois, USA) for analy-
sis. Continuous data were described using mean with standard
deviation (SD). Number and Frequencies (%) were used for express-
ing categorical variables. The p-value was calculated using a T-test
and the values<0.05 were considered as significant. Pearson Corre-
lation test was used to calculate the correlation between variables.
3. Results
A total of the 100 participants with AHDH disease 26% were
girls and %74 were boys. The mean age was 8.48 ± 2.52 years.
The mean height, mean weight, and mean BMI of the individuals,
were 129.68 ± 15.55 cm, 31.37 ± 11.6 kg, and 18.22 ± 3.95, respec-
tively. After 3 months, none of the children had abnormal blood
pressure based on their age, height, and gender. However, the
mean of both systolic and diastolic blood pressures significantly
increased compared with baseline (p < 0.001). Similarly, we saw
a statistically significant increase in the MAP, which was within
the normal range (p < 0.001). The mean of pulse pressure was ele-
vated in patients after three months, but these changes were not
significant (p = 0.059); heart rate insignificantly elevated as well
(p = 0.101). Table 1 fully covers the changes in the mean of the
measured blood pressure indices, heart rate, QT interval, and LV
indices in echocardiography after the follow-up.
4. Discussion
The ADHD effects on the cardiovascular system can be catego-
rized into two major aspects: effects of the disorder itself e.g.
through manipulating the sympathetic system and effects of the
medications used to treat. The two major key findings of the pre-
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date, the blood pressure indices increased significantly however
the QT interval did not change significantly.
Psychosocial therapy combined with pharmacotherapy, with
methylphenidate is the first-choice medication for ADHD in
school-aged children [34,35]. Although first-line drugs for ADHD
are considered safe, cardiovascular based personal and familial his-
tory alongside with complete physical examination including base-
line height, weight, blood pressure, and heart rate should be
acquired before the initiation of the treatment [36]. Reports related
to sudden deaths of patients, mainly children, treated by these
drugs have raised the question of whether these medications
increase the risk of cardiovascular events [37]. On the other hand,
numerous massive cohort studies have not demonstrated any
increased risk of life-threatening cardiovascular events among
children treated by stimulants compared with the general popula-
tion [38]. However, sudden death remains an extremely rare event
and not be attributed to methylphenidate as there is no clear evi-
dence supporting this association [39].
Long term use of amphetamines is shown to slightly elevate the
patients’ HR and BP [40]. A recent review showed ADHD medica-
tions cause modest elevations in resting heart rate and blood pres-
sure, in addition, other adverse effects due to ADHD stimulants
included arrhythmia, nonischemic cardiomyopathy, Takotsubo
cardiomyopathy, and sudden death [41]. Our results indicate that
treatment with stimulating agents for 3 months increases the
blood pressure and heart rate but these alterations remain within
the normal range. However, we assume that this increasing trend
may suggest the probability of an amplified risk of developing
HTN in the future.
Rapport et al. had investigated the cardiovascular effects of
short-term treatment with intermittent release methylphenidate
[42]. They Reported elevations of 3 to 10 bpm in heart rate, 3.3
to 8 mm Hg in SBP, and 1.5 to 14 mm Hg in DBP of patients [42].
Another study showed that treatment with stimulants for 4 weeks
causes no meaningful alterations in BP and pulse rate. This may be
proof of the safety of short-term treatments with these drugs [43].
Our study supports this statement as our results show that alter-
ations in blood pressure indices did not lead to hypertension in a
short period (3 months). However, the results should be inter-
preted with caution since the mentioned indices were still
increased.
Several studies showed ADHD medication increase in mean
blood pressure, heart rate, and QT interval in children, adolescents,
and adults [12,16,44]. Biederman J. et al conducted a study on
adults with ADHD in which they used OROS methylphenidate for
6 weeks and reported that methylphenidate was associated with
statistically significant increases in systolic and diastolic blood
pressure and heart rate but with a statistically significant decrease
of QT-interval [45]. In another study, methylphenidate causes an
increase in HR as well as increases in both systolic and diastolic
BP, but no adverse effect in cardiac depolarization and repolariza-
tion duration or homogeneity such as HR-corrected QT and JT
intervals or cardiac dispersion values [46]. Ilgenli TF. et al assessed
the acute effect (2 h after administration) of methylphenidate on
QT-interval duration and dispersion in children with ADHD and
showed that methylphenidate reduced QT-dispersion, corrected
QT-dispersion, maximum QT-interval but increased minimum
QT-interval [47]. The evaluation of acute cardiovascular effects of
immediate-release methylphenidate in children and adolescents
with ADHD by Lamberti M. et al demonstrated no significant
changes in ECG parameters [48]. In the present study, the QT-
interval incremental trend was non-significant.
Given that the LVOT-CSA is constant, any change in the SV and
CO is highly dependent on variations in the LVOT VTI; the HR asso-
ciates to CO as well [33,49,50]. In addition, LVOT-VTI can predict3
outcomes in selected populations [51]. Kara T. et al demonstrated
that methylphenidate usage in children did not damage cardiovas-
cular function at short-term follow-up of echocardiographic
parameters [52]. According to our results, there were no significant
differences between baseline and 3-month follow-up echocardio-
graphic findings, such as LVEDd, LVESd, and LVOT-VTI.
According to one of the most comprehensive comparative anal-
yses of the efficacy and tolerability of drugs for ADHD in different
age groups, first-choice medications for the short-term (12 weeks)
treatment of ADHD in children/adolescents and adults are methyl-
phenidate and amphetamines, respectively [53]. This large
network analysis could not provide sufficient information for
long-term timepoints (26 and 52 weeks). Our findings are consis-
tent with this analysis that methylphenidate is safe in short-time
management of ADHD in children and adolescents. The evaluation
of long-term effects of ADHD medication should be taken into
consideration in the future studies.
Of note, the use of stimulants did not cause any significant
changes in adverse cardiovascular events in children and adults
[38,44,54]. Despite non-pathological increases in BP, HR, and QT
interval, because increased BP, HR, and QT interval are associate
with cardiovascular morbidity and mortality during adulthood so
pediatric patients treated with ADHD medication need to be mon-
itored for HR and BP, closely and regularly.
5. Limitations
Perhaps the most important limitations of the current study are
its small sample size and short follow-up duration. Future studies
with longer follow-up durations and larger sample size could be of
benefit. evaluating novel ECG indices would be interesting.
6. Conclusions
The results of this study indicate that short-term treatment of
ADHD diagnosed children with CNS stimulants does not have a
meaningful relationship with altered blood pressure indices, while
all indices were increased in a non-pathological range after
3 months of follow up. The QT prolonged after three months but
this was nonsignificant. Of note, we recommend studies with lar-
ger sample sizes and longer follow-up durations be performed to
determine the precise effects of CNS stimulating drugs on blood
pressure indices, HR, and ECG parameters.
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